ADORA2A and myeloid sarcoma: Indeed, in human lymphocytes, A2AR agonist inhibits the release of proinflammatory cytokines, cell proliferation, the expression of the adhesion molecule VLA-4, and the activation of the transcription factor NF-κB; these effects were more evident in lymphocytes from MS patients in comparison to healthy subjects, in line with upregulation of A2ARs in MS lymphocytes (Vincenzi et al., 2013).